2 assets in Squamous Cell Carcinoma Of The Small Intestine

Therapeutic assets addressing Squamous Cell Carcinoma Of The Small Intestine, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Squamous Cell Carcinoma Of The Small Intestine	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Squamous Cell Carcinoma Of The Small Intestine	National Cancer Institute (NCI)	P2	CCC (53)